miONCO-Dx - Multi-Cancer testing for Early Detection
Research type
Research Study
Full title
Optimisation and evaluation of the miONCO-Dx test for early detection of multiple cancers
IRAS ID
317351
Contact name
Paul Skipp
Contact email
Sponsor organisation
University of Southampton
Duration of Study in the UK
4 years, 0 months, 0 days
Research summary
Almost half of all cancers worldwide are diagnosed at stage 3 or later, where survival rates are significantly lower. There is a worldwide effort to increase the proportion of cancers identified at early stages (stages 1 and 2) including the vision set out by our NHS whereby they aim to identify 75% of all cancers at an early stage by 2028.
Using publicly available data of over 20,000 patient's blood, we used artificial intelligence and machine learning to identify biomarkers in the blood which could predict cancer with an accuracy of >99% across 12 different cancer types. Furthermore, these markers are also able to correctly identify the location of the tumour with an accuracy of up to 96%. The aim of this study is to adapt the test into a faster and more cost effective alternative and to assess its performance. We will initially be studying 3-5 cancers to optimise the assay but will then be expanding to the full 12 cancers. There is also reasonable evidence that our test can be extended for the detection of additional cancers.
This project will provide the necessary data for optimisation and evaluation in preparation for future follow up studies towards CE/UKCA marking to enable commercialisation of the test which could revolutionise cancer screening, diagnosing people earlier, preventing cancer progression and improving patient survival.
REC name
South Central - Berkshire B Research Ethics Committee
REC reference
24/SC/0269
Date of REC Opinion
9 Aug 2024
REC opinion
Favourable Opinion